An RPCH outpatient visit represents a face-to-face encounter between the patient and a health professional during which the RPCH outpatient services are furnished. Encounters with more than one health professional, and multiple encounters with the same health professional, which take place on the same day constitute a single visit, except for cases in which subsequent encounters occur on the same day due to an injury or illness requiring additional diagnosis or treatment different from the injury or illness associated with the initial encounter. These subsequent encounters are counted as separate visits. Under either method of payment the RPCH files a year-end cost report in order to make final settlement. If you choose the all-inclusive method of payment, you cannot bill late charges.
Twenty placebo-controlled trials of the subcutaneous administration of sumatriptan, 7 ; a serotonin 5-HT1B 1D receptor agonist, have been performed. In all these trials sumatriptan manifested significantly superior effects on migraine to placebo. In other words, the remission rate of headache by subcutaneous injections of 6 mg of sumatriptan is 65 to 80% and of that of 3 mg subcutaneous injections is 57 to 75%; both showing a superior effect to that of placebo. The incidence of adverse reactions at that time was significantly higher in the subcutaneous sumatriptan group than in the placebo group. Injection site pain redness and chest discomfort were recognized as adverse reactions. Furthermore, 20 placebo-controlled double-blind trials8 ; of the effect of oral administration of sumatriptan were conducted. In all these trials the sumatriptan administration groups showed a significantly superior effect to the placebo groups. In Japan, sumatriptan injection 3 mg ; has been available since April 2000, while an oral agent sumatriptan 50 mg tablet ; has been available since August 2001. Also, a nasal spray will be approved in the future. Sumatriptan 6 mg.
Segregation analyses regarding the mode of transmission of OCD, a methodologic approach that does not require specification of a particular genetic model should be more efficacious in identifying some of the OCD susceptibility genes. Furthermore, as discussed by Pauls 118 ; exclusive reliance on large multigenerational families for the detection of linkage is not indicated when the disorder is common and the most likely mode of transmission is multigenic. At the present time, there are no published linkage studies of OCD. Thus, the remainder of this chapter focuses on association studies of candidate genes. Association Studies Genes of the Serotonergic System Gene testing in OCD has begun, focusing on candidates derived from the hypothesized etiologic importance of the serotonin and dopamine systems. With respect to the serotonin system, the serotonin transporter gene SLC6A4 ; has been implicated in OCD as the site at which SSRIs initially exert their effects. Lesch and co-workers 119 ; evoked considerable interest in the transporter gene by demonstrating an association between the short allele of the 44bp insertion deletion polymorphism in the promoter region and the anxiety-related personality traits of Neuroticism and Harm Avoidance in 505 individuals. This polymorphism has been shown to affect gene function in vitro; the longer allele l ; is associated with threefold increases in gene expression 120 ; . Furthermore, the l allele of this polymorphism has been associated with elevated blood SLC6A4 levels in a sample of 70 OCD subjects 121 ; . The first study of the promoter polymorphism revealed a trend toward increased homozygosity l l and s s ; in OCD patients, but the overall results were indeterminate 122 ; . Subsequent investigation of OCD trios revealed significantly increased transmission of the l allele to OCD probands 123 ; . The 5-HT2A-receptor gene has been investigated in an association study, including 67 OCD patients 124 ; with inconclusive results. Kim and associates sequenced the 5HT2B-receptor 125 ; . One single nucleotide polymorphism was found in intron 1 of the gene, but no evidence for a functional mutation was found. Finally, another association study by Cavallini and colleagues 126 ; of a 5-HT2C polymorphism in 109 OCD subjects and matched controls also gave negative results. Very recently, an association between OCD and a polymorphism of the 5-HT1D receptor gene has been reported 127 ; . This result appears to be particularly interesting with respect to the pathogenesis of OCD and surely deserves further investigation. The 5-HT1D receptor is a terminal autoreceptor involved in the regulation of 5-HT transmission, and challenge studies with selective ligands i.e., sumatriptan ; 48 ; showed an acute worsening of OC symptoms, whereas chronic treatment with the same com.
L-dopa. These parallelisms break down, however, when one considers that anticholinergics, which are hallucinogens, have acted in the opposite direction in tests such as these 4-6, 24 ; . The sum of this evidence proves that the regulatory functions of this cyclase have not been fully defined as yet. It is obviously desirable that this enzyme be tested for its responses to hallucinogenic drugs. We are currently determining whether its activity is quantitatively correlated with neurological responses to drugs as opposed to the qualitative parallelisms drawn thus far. These uncertainties, viewed with the fact that the caudate is a large complex cerebral structure, make it probable that we have missed some important regulatory function of the cyclase in the caudate, a function perhaps radically different from any of those mentioned here, for example, sumatriptan dosage. Specifically, the total migraine healthcare costs were 41% lower after starting treatment with sumatriptan.
Respondent commented that: `You need to express your work in practical, non-academic terms to the service.' Another agreed that: `It's not easy to understand I had to read through the results twice. More user-friendly language please!' Apart from that, reactions to the questionnaires were positive ` [the questionnaire] was easy to follow and the format was consistent.' In summary, these suggestions support the need for a better integration of academic and health care knowledge and skills to achieve the best possible tools to measure and analyse risk perceptions toward technology within NHS hospitals.
The pharmaceutical industry has an obligation to provide the information ensuring optimal use of their products. This is the role of the patient information leaflet and packaging information. In principle, this type of information is written with the patient in mind. In contrast, the summary of product characteristics is aimed at the health care professional. SERIOUS AND REPEATED ABUSES BY THE PHARMACEUTICAL INDUSTRY In practice, drug companies have failed to fulfil their duty to inform via the patient leaflet and SPC. By completely blurring the dividing line between information and promotion, they have developed highly effective promotional tools and methods that ignore the very special nature and utilisation of the "merchandise" they produce. Information for health professionals has given way to promotional material overstating benefits and minimising risk through every available medium. The place of the SPC has become highly restricted, and in some cases has simply evaporated, as witnessed by the majority of medical sales visits to practitioners. The spread of exaggerated or deceitful information on the benefits of drugs, and the omission of information on adverse effects, is regularly decried by regulatory agencies and independent monitoring networks such as MaLAM in Australia, Prescrire's medical rep monitoring network in France, No Free Lunch in the United States, or GRAS in Belgium, etc 12, 13, 14, ; . Regarding information for the general public, the pharmaceutical industry has given up trying to create informative package labelling and patient leaflets, concentrating rather on increasingly intensive promotion in the various media. Initially advertising was restricted to self-treatment medications, but this promotional activity is now spreading to an increasing number of prescription-only drugs. This is especially the case in the United States, particularly via companies' websites, which are also accessible in Europe. In addition, drug companies are already using all the other available media, intensively promoting their products, including prescription drugs, either directly or through the use of opinion leaders. The first major campaign of this type to hit Europe was for sumatriptan in the early 1990s. Since then, the number of such campaigns has exploded, and now concerns not only products used in obesity or erectile dysfunction, but also in osteoporosis, hypertension or some cancers. Is the drug industry nevertheless informing patients, or conducting information campaigns on serious health problems? No. The industry's sole preoccupation now, in the current context of cut-throat financial competition and the all-powerful shareholder, is to promote their products in any way possible, including DTCs. THE DOWNSIDE OF DTC PROMOTION Some say that DTC promotion would have positive consequences, for example, helping to inform patients who are unaware of they have a medical condition. They say that the poorly informed "consumer", who is desperately seeking information on drugs, would appreciate DTC promotion. Yet the negative consequences of promotional abuses are already visible today. In the United States, for example, where DTC promotion is widespread and legal, there has been a massive increase in prescriptions and sales ; of prescription-only drugs that have been intensively promoted to the public. Compared to 1998, prescriptions rose by a staggering 34% in 1999 for the first 25 prescription drugs that had been the subject of DTC promotion. This compared with only a 5% rise overall in other prescription drugs. In 1999, drug companies spent 180 million dollars on DTC promotion -- 40% more than in 1998 16 and tagamet. Experience limited duration benefit from subcutaneous sumatriptan. In the current study, the cost of lost workplace productivity was estimated at .66 per placebo-treated attack and .92 per sumatriptan-treated attack for an estimated benefit of .74 per attack treated with sumatriptan. Of note, the estimated benefit of .74 per attack would not come close to covering the cost of sumatriptan by injection average wholesale price as of June 2000 is almost per injection ; but does just cover the cost of a 50-mg tablet of sumatriptan average wholesale price as of June 2000 is about per pill ; . However, such an analysis does not consider the fact that the benefit of sumatriptan extends into the patients' nonwork hours. I confident that patients would judge the work hour plus after work hour benefits of triptan therapy to be worthwhile even if they had to pay a larger portion of the drug cost. The article by Schulman et al5 demonstrates that selfadministered subcutaneous sumatriptan is effective in the workplace. All physicians who see patients with migraine should recommend the use of triptans to appropriate patients who work and, moreover, suggest triptans to the rescue when the patients are at work. J. D. Bartleson, MD Mayo Clinic Rochester, Minn. Predict the potential effects of these chemicals in humans. One research team measured the carcinogenicity of sucralose in rats1 and mice, 2 and a second research team measured the oncogenicity of tributyl phosphate in rats.3 These studies are invalidated by the standard criticisms of toxicity experiments on nonhuman animals. It is never possible to extrapolate animal findings to humans with confidence. To do so, it is necessary to know, in addition to the animal data, results of human studies. However, with knowledge of human data, the animal data are unnecessary and possibly misleading ; . What may be carcinogenic in animals may not be so in humans, and vice-versa. In a National Cancer Institute study, only 7 of 19 known human carcinogens caused cancer in rodents given high doses over their lifetimes, using the Standard National Cancer Institute Protocol.4 A well-known toxicology text reads, "All known chemical carcinogens in man, with the possible exception of arsenic, are carcinogenic in some species but not in all laboratory animals."5 John Leavitt of the Linus Pauling Institute has written of severe drawbacks using animals to understand human cancer.6 Science editor Philip Abelson has asked, "Are humans to be regarded as behaving biochemically like huge, obese, inbred, cancer-prone rodents?"7 An editorial in Clinical Oncology states "Occasionally, individuals have had the temerity to ask why so much effort is devoted to the study of animal tumors rather than the readily available, but emotionally disturbing, human problems. It is in fact hard to find a single common solid human neoplasm where management and expectation of cure have been markedly influenced by the results of laboratory research. Most human cancers behave differently from the artificially produced animal model and.many clinicians must wonder why so little attention appears to be paid to the human condition."8 An Office of Technology Assessment report on the causes of cancer attached more weight to epidemiologic data than to animal experiments because its authors argued that animal tests "cannot provide reliable risk assessments."9 It is not surprising, that, in general, animal tests of carcinogenesis have proved inconsistent.10 While the shorter life spans of mice may be very convenient for researchers, this is hardly a benefit when results from a species requiring 45 days to grow from birth to adulthood are applied to humans, who require more than 6, 500 days to reach adulthood. This is especially troubling when considering prenatal exposure to drugs. Mice have a gestational period of only 20 days, while in humans it typically runs about 270 days, a disparity that can contribute to the dramatic differences in developmental toxicity of drugs between species tested and humans. In general, tumors prevalent in rodents, such as pituitary, liver, and thyroid tumors, are uncommon in humans, whereas tumors common in humans, such as those of the prostate, colon, and rectum, are rare in rodents.11 The usage of mice for carcinogenicity testing is problematic because the species has a high spontaneous incidence of tumors. Additionally, mouse mammary, lymphomatous, hepatic, and pulmonary tumors are questionable as legitimate sources of data from which to understand human cancer.12, 13 Liver and lung tumors, in particular, are difficult because "their malignancy is often and temovate. If you are unable to reach us and you have any of the symptoms listed above, you should go to the emergency room. If you go to the emergency room, bring the Mifeprex Danco booklet that was given to you on your first visit. When you call, be ready to tell us: The telephone number of an open drug store that you can use. Your temperature within the last hour. The number of pads you have used within the last hour. ` Clinician signature Patient signature PLACE SIGNED COPY IN CHART. 5 22 06 AB-33 Reviewed on: Copy provided to patient!
In reply: We appreciate Mr McGuffin's interest in our case report. However, we disagree with his claim that the known cardiovascular effects seen with intravenous administration of synephrine would not be expected when the drug is taken orally. No matter the route of delivery, pharmacokinetics support similar physiological effects once a drug has reached steady-state concentrations. Because steady-state levels were likely present in our patient, the references mentioned1, 2 are relevant. We acknowledge that the doses of synephrine used in some studies have been higher than those ingested by our patient. However, in our report, we highlighted the fact that CortiSlim also contains numerous other vasoactive compounds that might act synergistically with synephrine. Indeed, a recent small randomized, double-blind study showed that a multicomponent dietary supplement containing synephrine increases blood pressure and heart rate in healthy adult subjects.3 We did not purport that the use of a bitter orangecontaining supplement caused hypertension in our patient, and we.
© 2007